ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer
The inhibition of ERK5 is a potential complementary strategy for countering FAK inhibitor resistance in patients with lung ...
epithelial cell death and activation of proinflammatory pathways, which gives rise to the clinical entity known as ventilator-induced lung injury (VILI).
Rhabdomyolysis-induced AKI (RIAKI) is caused by myoglobin and heme released from muscle cells, excess reactive oxygen species (ROS), and ... Recent studies have highlighted macrophages as key players ...
Alveolar macrophages, residing on the lung’s inner surface, constitute 55% of pulmonary immune cells. They can polarize into two distinct phenotypes: the classically activated (M1) and the ...
such as epithelial cell growth factors, reduce ALI in animal models. Reactive oxygen species are enhanced in ALI and propagate inflammatory cascades and lung injury. Antioxidants can attenuate ALI ...
a randomized phase III trial of carboplatin- or cisplatin-pemetrexed-pembrolizumab versus carboplatin- or cisplatin-pemetrexed in 492 patients with stage IV nonsquamous non–small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback